Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression

Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards and Duncan I. Jodrell
Yann Wallez
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yann Wallez
  • For correspondence: Yann.Wallez@cruk.cam.ac.uk Fran.Richards@cruk.cam.ac.uk
Charles R. Dunlop
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles R. Dunlop
Timothy Isaac Johnson
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siang-Boon Koh
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
2Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
3Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Siang-Boon Koh
Chiara Fornari
4Safety and ADME Translational Sciences Department, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James W.T. Yates
5Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Bernaldo de Quirós Fernández
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Lau
5Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances M. Richards
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frances M. Richards
  • For correspondence: Yann.Wallez@cruk.cam.ac.uk Fran.Richards@cruk.cam.ac.uk
Duncan I. Jodrell
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-18-0010 Published August 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    PDAC sensitivity to AZD6738 monotherapy. A, Frequency of alterations in genes reported to confer sensitivity to ATR inhibition, from the Cancer Genome Atlas cohort of PDAC samples (http://www.cbioportal.org). B and C, Human (B) and mouse (C) PDAC cell lines were grown in increasing concentrations of AZD6738 for 3 days to generate dose–response curves using the SRB assay. The GR metrics R package (developed by Clarke and colleagues, 2017) was used to generate normalized growth rate inhibition (GR) values, thus controlling for the different doubling times of the cell lines. Drug concentrations that bring the GR value to zero are cytostatic, whereas negative GR values represent cytotoxicity. Each point represents the mean of three independent experiments ± SEM. D and E, Comparison of GR50s for AZD6738 alone or in combination with low dose of gemcitabine [5 nmol/L for the most sensitive mouse PDAC lines (D) or 10 nmol/L for KPCFT79653 and human lines (E)]. Data are represented as mean ± SEM. Multiple t tests were performed and statistical significance determined using the Holm–Sidak method; **, P ≤ 0.01; ***, P ≤ 0.001, and ns, P > 0.05.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    AZD6738 abrogates the gemcitabine-induced checkpoint activation. A, Western blotting for K8484 cells treated as indicated for 7 hours. B, Western blotting for MiaPaCa-2 cells treated as indicated for 24 hours. C, Western blotting for MiaPaCa-2 and Panc-1 cells treated as indicated for 30 hours. D, MiaPaCa-2 cells were treated with scramble or ATM-specific siRNA. After 24 hours, cells were treated as indicated for 24 hours, and lysates were immunoblotted. E, Western blotting for MiaPaCa-2 and Panc-1 cells treated as indicated for 30 hours. Arrowheads indicate the bands of interest. Note that the upper band in the pChk1-S345 blots appearing in lysates of MiaPaCa-2 treated with the combination is most likely the result of a cross-reaction with p-Chk2.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    AZD6738 and gemcitabine synergistically inhibit cell growth in a panel of PDAC cell lines. A, MiaPaCa-2 and Panc-1 cells were treated with AZD6738 and gemcitabine in an 8 × 8 concentration grid for 72 hours. Cell viability was determined by measuring the total protein content using the sulforhodamine B assay. The experimental data (left, values are percentage growth inhibition compared with control) were analyzed independently with the two synergy models (Bliss and Loewe) using the Combenefit software. Data, mean ± SD, n = 3. B and C, MiaPaCa-2 cells were treated with AZD6738 and gemcitabine in a 6 × 8 concentration grid for 24 hours. The drugs were washed out and replaced with fresh medium containing the YOYO-3 Iodide cell-impermeant dye to follow cell death. Three random fields per sample were imaged by time lapse microscopy every 3 hours for 4 days. Cell growth was analyzed using cell confluency data and expressed as percentage of growth inhibition compared with control (B, left plot) and Combenefit software for synergy analyses (B, 2 right plots). Growth curves (C, left plot) and cell death accumulation (C, right plot) from control cells or cells treated with indicated concentrations of AZD6738 and gemcitabine. Data, mean ± SEM, and n = 2. D, Clonogenic survival of Panc-1 and MiaPaCa-2 cells plated at very low density and exposed to the indicated drug combinations for 24 hours before washout. Cells were left to grow for 8 days after washout. Data, mean ± SD, n = 3.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Scheduling of the combination of AZD6738 with gemcitabine. A, Four cell lines from the KPC mouse model were plated at low density and treated with the first condition for 16 hours, then the medium was replaced with the second condition and cell growth was monitored by time lapse microscopy every 3 hours for 4 days. Drugs were used at the GI50 (72 hours) concentrations. B, Cells were incubated with 10 nmol/L gemcitabine for 16 hours and then fixed at the time point shown after washout into fresh medium or with 300 nmol/L ATRi. Immunofluorescence followed by quantitative microscopy was realized to obtain the percentage of cells positive for γH2AX. C, Dose-schedule schematic (left) of the in silico modeling of AZD6738 mouse PK for the gut, circulating, and peripheral compartments (right).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    The combination of AZD6738 + gemcitabine achieves antitumor effect and improves survival, in a subcutaneous allograft of a KPC cancer cell line. A, Tumor volume of K8484 allografts. Ten mice per group were treated as indicated in the legend (middle of the figure) for 3 consecutive weekly cycles (see dose/schedule schematic in Fig. 4C). After a 1-week break, treatment was resumed for another 3 weeks. Data are represented as mean ± SEM. +, Culled animals. B, Changes in individual tumor volume between D14 and D25 (when all mice were still alive). C, Changes in individual tumor volume between D46 and D60 (only 2 mice remaining in the gemcitabine alone group). D, Kaplan–Meier survival curves. E, Body weight change relative to pretreatment body weight. Data are represented as mean ± SEM. F, Quantification of γH2AX-positive cells from tumors IHC. Data are represented as mean ± SD. A one-way ANOVA analysis with Tukey pairwise comparisons was performed; **, P ≤ 0.01; ****, P ≤ 0.0001, and ns, P > 0.05.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    The combination of AZD6738 + gemcitabine induces tumor regression in a subgroup of KPC tumors. A, Schematic of the study and dosing schedule. B, Changes in individual tumor long diameter between day –1 and day 12. Dotted lines represent the mean of each group. A one-way ANOVA analysis was performed with Tukey pairwise comparisons; **, P ≤ 0.01 and ns, P > 0.05. During the 12-day study, in the gemcitabine-alone group, 2 mice had a “stable” (<10% diameter change) disease, whereas 16 had a “progressive” (>10% diameter change) disease. In the combination group, 4 mice had a stable disease, whereas 6 had a progressive disease. If the probability to have a stable disease in the combination group is the same as in the gemcitabine alone group (i.e., 2/18), we would expect to observe 4 or more stable disease out of 10 animals only 1.84% of the time (P = 0.018). C, Quantification of γH2AX-positive cells from tumors IHC. Data are represented as mean ± SD. A one-way ANOVA analysis with Tukey pairwise comparisons was performed; ***, P ≤ 0.001.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Summary of AZD6738 sensitivity and synergy with gemcitabine across the panel of PDAC cell lines

    AZD6738 GR50SUM_SYN_ANTSUM_SYN_ANT_WEIGHTEDSYN_MAXSYN_SPREAD
    Without gemWith gemLOEWEBLISSAVGLOEWEBLISSAVGLOEWEBLISSAVGLOEWEBLISSAVG
    MOUSE LINESK8484536158Gem 5 nmol/L51184861132210.800.620.71
    TB32048710355112217915122337300.800.790.79
    DT80827633950840532323230.520.660.59
    TB31456771359133122919142966470.690.700.69
    KPCFT7965326091346Gem 10 nmol/L15292261393655450.680.730.71
    HUMAN LINESSW199093514561335232132324241.611.271.44
    Capan-11572216531483616263535351.521.281.40
    ASPC119836915131412413182926271.431.321.38
    HPAFII32394279039643912253821291.621.571.60
    Capan-2477522086257601210113333331.521.481.50
    MiaPaCa-298448549185885749535260561.371.231.30
    Panc-1>3000034961661351519674856157591.761.651.71
    • NOTE: GR50 for all cell lines was obtained using the GR metrics R package (developed by Clarke and colleagues, 2017). Mouse and human lines are ranked by increasing GR50 for AZD6738. Summing of synergy and antagonism was used to compare combinations using Metrics obtained from Combenefit. Both Bliss, Loewe models, and the average (AVG) are shown. SUM_SYN_ANT is the sum of synergy and antagonism observed in concentration logarithmic space. For instance, an integrated synergy of 50 is equivalent to an extrasynergistic effect of 50%, which is spread over a square of 1 log x 1 log in the 2-d log-concentration space. Both antagonistic and synergistic effects are considered in this metric. The integrated weighted synergy SUM_SYN_ANT_WEIGHTED incorporates a weight based on the dose response, which biases the total score toward synergy achieving highest effect. Hence, a synergy of 50% leading to a combined full effect (100%) will have more weight than if the corresponding effect was only 20% or 30%. Both antagonistic and synergistic effects are considered in this metric. SYN_MAX is the maximum level of synergy observed. SYN_SPREAD is a measure of synergy spread in the logarithmic concentration space.

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    • Figure S1 - AZD6738 abrogates the gemcitabine-induced checkpoint activation
    • Figure S2 - AZD6738 and gemcitabine synergistically inhibit cell growth in a panel of PDAC cell lines
    • Table S1 - Genetic alterations likely to sensitize to ATR inhibition in the human PDAC cell lines
PreviousNext
Back to top
Molecular Cancer Therapeutics: 17 (8)
August 2018
Volume 17, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards and Duncan I. Jodrell
Mol Cancer Ther August 1 2018 (17) (8) 1670-1682; DOI: 10.1158/1535-7163.MCT-18-0010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards and Duncan I. Jodrell
Mol Cancer Ther August 1 2018 (17) (8) 1670-1682; DOI: 10.1158/1535-7163.MCT-18-0010
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Discovery of a Novel Anticancer Therapeutic
  • eFT226, a Selective Inhibitor of eIF4A-Mediated Translation
  • Peptide Inhibiting Breast Cancer by Disrupting SND1–MTDH
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement